Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.

Lane H-Y, Liu Y-C, Huang C-L, Chang Y-C, Liau C-H, Perng C-H, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63(1):9-12. DOI: 10.1016/j.biopsych.2007.04.038. PubMed PMID: 17659263.

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.

Lane H-Y, Huang C-L, Wu P-L, Liu Y-C, Chang Y-C, Lin P-Y, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006;60(6):645-9. DOI: 10.1016/j.biopsych.2006.04.005. PubMed PMID: 16780811.

Effects of typical and atypical antipsychotics on human glycine transporters.

Williams JB, Mallorga PJ, Conn PJ, Pettibone DJ, Sur C. Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res. 2004;71(1):103-12. DOI: 10.1016/j.schres.2004.01.013. PubMed PMID: 15374578.

D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy.

Sacchi S, Rosini E, Pollegioni L, Molla G. D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Curr Pharm Des. 2013;19(14):2499-511. PubMed PMID: 23116391.

Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis.

Veerman SRT, Schulte PFJ, Begemann MJH, Engelsbel F, de Haan L. Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. Pharmacopsychiatry. 2014;47(6):185-94. DOI: 10.1055/s-0034-1383656. PubMed PMID: 25002291.

Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes.

Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol. 2012;165(5):1543-55. DOI: 10.1111/j.1476-5381.2011.01638.x. PubMed PMID: 21880034.

The McLean-Harvard First-Episode Project: Early Course in 114 Cases of First-Episode Nonaffective Psychoses.

Tohen M, Khalsa H-MK, Salvatore P, Zarate CA, Strakowski SM, Sanchez-Toledo JP, et al. The McLean-Harvard First-Episode Project: Early Course in 114 Cases of First-Episode Nonaffective Psychoses. J Clin Psychiatry. 2016;77(6):781-8. DOI: 10.4088/JCP.14m09414. PubMed PMID: 27232651.

Prenatal Nicotine Exposure and Risk of Schizophrenia Among Offspring in a National Birth Cohort.

Niemelä S, Sourander A, Surcel H-M, Hinkka-Yli-Salomäki S, McKeague IW, Cheslack-Postava K, et al.. Prenatal Nicotine Exposure and Risk of Schizophrenia Among Offspring in a National Birth Cohort. Am J Psychiatry. 2016;173(8):799-806. DOI: 10.1176/appi.ajp.2016.15060800. PubMed PMID: 27216261.

Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia.

Oh N, See YM, Remington G, Lee J. Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia. J Clin Psychopharmacol. 2016;36(4):403-5. DOI: 10.1097/JCP.0000000000000513. PubMed PMID: 27187561.

Psychoeducational training for schizophrenic patients: background, procedure and empirical findings.

Hornung WP, Kieserg A, Feldmann R, Buchkremer G. Psychoeducational training for schizophrenic patients: background, procedure and empirical findings. Patient Educ Couns. 1996;29(3):257-68. PubMed PMID: 9006241.